Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

1.650 -0.050 (-2.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 403,749
Open 1.700
Bid (Size) 1.680 (50)
Ask (Size) 1.750 (2)
Prev. Close 1.700
Today's Range 1.610 - 1.750
52wk Range 1.260 - 6.860
Shares Outstanding 971,191,902
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga

Performance

YTD
-59.36%
-59.36%
1 Month
+15.38%
+15.38%
3 Month
-26.01%
-26.01%
6 Month
-59.36%
-59.36%
1 Year
-61.72%
-61.72%

More News

Read More
Adaptimmune Therapeutics's Return On Capital Employed Insights
Via Benzinga
Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
Via Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Adaptimmune Therapeutics: Q1 Earnings Insights
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Via Benzinga
Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET
Via Benzinga
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Adaptimmune Therapeutics: Q4 Earnings Insights
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Via Benzinga
Earnings Scheduled For March 14, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Crashing Today
Via The Motley Fool
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Adaptimmune Therapeutics: Q3 Earnings Insights
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Via Benzinga
Exposures Product Safety
Why Adaptimmune Therapeutics Was Sinking This Week
Via The Motley Fool
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
Via Benzinga
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.